以第一代EGFR-TKI类药物为例，一旦患者发生临床耐药，需要再次进行肿瘤话检，约50%的患者在原先敏感突变基因的基础上发现了EGFR20号外显子T790M突变，这部分患者可以接受“一代后续三代”的治疗方式，即将第一代 ...

EGFR mutations, including L858R and T790M, are common in NSCLC. TKIs like erlotinib and gefitinib target these mutations but lose effectiveness within a year due to secondary mutations.

LAS VEGAS , March 11, 2025 /PRNewswire/ -- DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which ...